DDInter1607 DDInter899
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Ritonavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1A2
Ritonavir {u} (Compound) upregulates {v} (Gene) AGR2
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Breast Cancer Resistance Protein Inhibitors
Ritonavir {u} (Compound) downregulates {v} (Gene) NT5DC2
Ritonavir {u} (Compound) causes {v} (Side Effect) Blood triglycerides increased
Ritonavir (Compound) resembles Atazanavir (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound)
Ritonavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Ritonavir (Compound) binds SLCO1A2 (Gene)
Ritonavir (Compound) upregulates AGR2 (Gene)
Ritonavir (Compound) is included by Breast Cancer Resistance Protein Inhibitors (Pharmacologic Class)
Ritonavir (Compound) downregulates NT5DC2 (Gene)
Ritonavir (Compound) causes Blood triglycerides increased (Side Effect)